• Explore /
  • Poster
  • / NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.

NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.

Abstract Poster

Authors

null

Jonathan R. Strosberg

Moffitt Cancer Center, Tampa, FL

Jonathan R. Strosberg , Edward M. Wolin , Beth Chasen , Matthew H. Kulke , David L Bushnell Jr., Martyn E. Caplin , Richard P. Baum , Pamela L. Kunz , Timothy J. Hobday , Andrew Eugene Hendifar , Kjell E. Oberg , Maribel Lopera Sierra , Dik J. Kwekkeboom , Philippe B. Ruszniewski , Eric Krenning

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01578239

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 194)

DOI

10.1200/jco.2016.34.4_suppl.194

Abstract #

194

Poster Bd #

A4

Abstract Disclosures

Similar Posters

First Author: Jonathan R. Strosberg

Poster

2017 Gastrointestinal Cancers Symposium

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.

First Author: Jonathan R. Strosberg

First Author: Jonathan R. Strosberg

First Author: James C. Yao